GlobeNewsWire
07 May 2026, 06:44 UTC · 20w ago
Verdict
Headline takes no side. We score CPRX +0.80 — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company successfully settled patent litigation, securing exclusivity for FIRDAPSE in the US until January 2035.
More negative than 62% of ticker scores this week
Mentioned as a party that previously settled litigation, implying they were unable to bring a generic version to market early.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 35% of relationship scores this week
[mutual] Teva Pharmaceuticals sought to market a generic version of Catalyst's FIRDAPSE, resulting in patent litigation and settlement.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
1h ago
+3.2%
Price agrees with the score
$31.49 vs $30.52 close before publication (May 6) · not market-adjusted
CPRX chart →
